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Abstract
Background:   The relationship between breast cancer and organochlorine exposure is
controversial and complex. As estrogen receptor positive and negative breast cancer may
represent different entities of the disease, this study was undertaken to evaluate organochlorines
influence on breast cancer risk and survival according to receptor status.
Methods:  The background material stems from the Copenhagen City Heart Study (Denmark
1976-78). The breast cancer risk was investigated in a cohort nested case-control design including
161 cases and twice as many breast cancer free controls. The cases served as a cohort in the
survival analysis. Serum organochlorine concentrations were determined by gaschromotography.
Results:  The observed increased breast cancer risk associated with exposure to dieldrin derived
from women who developed an estrogen receptor negative (ERN) tumor (Odds ratio [OR] I vs.
IV quartile, 7.6, 95% confidence interval [95% CI] 1.4-46.1, p-value for linear trend 0.01). Tumors
in women with the highest dieldrin serum level were larger and more often spread at the time of
diagnosis than ERP tumors. The risk of dying was for the remaining evaluated compounds higher
among patients with ERP breast cancer when compared to those with ERN. In the highest quartile
of polychlorinated biphenyls (Σ PCB) it was more than 2-fold increased (Relative risk [RR] I vs. IV
quartile, 2.5, 95% CI 1.1-5.7), but no dose-response relation was apparent.
Conclusion:  The results do not suggest that exposure to potential estrogenic organochlorines
leads to development of an ERP breast cancer. A possible adverse effect on prognosis of hormone-
responsive breast cancers needs to be clarified.
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Background
Many organochlorines have become ubiquitous in the
environment and in the human body due to their resist-
ance to degradation and their high solubility in lipids,
which leads to accumulation in adipose tissue. Some of
these compounds are suspected of disrupting the endo-
crine system and thereby increasing the risk of hormone-
dependent disorders and diseases such as breast cancer
[1–3]. Epidemiological studies indicate that total lifetime
exposure to estrogen predict the risk of breast cancer
[4,5]. Estrogen also plays an important role for the prog-
nosis of breast cancer as treatment with the anti-estro-
genic drug tamoxifen improves the survival of
postmenopausal women with estrogen receptor positive
(ERP) breast cancer [6]. Furthermore, estrogen stimu-
lates proliferation of ERP breast cell lines and may there-
for be associated with ERP human breast cancers only
[7].
Previous studies of the potential effect of estrogenic or-
ganochlorines on breast cancer risk have yield inconsist-
ent results [8–23] and only a few has taken into account
estrogen receptor status (ER) [16,17,19]. In a small Cana-
dian study women with ERP tumors, but not those with
estrogen receptor negative (ERN) tumors, had a higher
DDE and PCB body burden compared to women with be-
nign breast disease [16]. An excess risk of developing an
ERP breast cancer associated with exposure to certain
PCB congener was also demonstrated in a study conduct-
ed in Sweden [19].
In the so far only study on breast cancer survival, an ad-
verse effect of exposure to dieldrin was identified, but ER
was not obtained at that stage [24].
It has been postulated that ERP and ERN are two differ-
ent entities of breast cancer having different biological
and etiological mechanisms. Thus, distinguishing be-
tween breast cancer which growth is dependent on estro-
gen and those which is not i.e. ERP and ERN tumors,
may have implications for studying potential estrogenic
organochlorines possible influence on breast cancer risk
and survival. Presented in this paper are results of anal-
ysis on breast cancer risk and overall survival while ac-
counting for ER of the primary tumors.
To avoid problems with multiple comparisons, the anal-
yses were restricted to organochlorines with estrogenic
properties or compounds that are indicators of previous
exposure to estrogenic ones.
Materiel and methods
The background material constitutes the Copenhagen
City Heart Study (CCHS), which in 1976-78 enrolled a
random sample of 10,317 women living within 10 wards
of the National University Hospital of Copenhagen, Den-
mark. This study was designed as a cohort-nested case-
control study, where the case group consisted of 268
women between 25 and 80 years of age diagnosed with
primary breast cancer between initiation of the CCHS
and end of follow up in 1993. They were identified
through computerized linkage to the Danish Cancer Reg-
istry using the unique 10-digit ID-number issued to each
resident in Denmark. As controls, a random sample of
536 women matched on age, and vital statistics was se-
lected from the remainder of the CCHS cohort. Informa-
tion on lifestyle factors, reproductive history, and
socioeconomic conditions was obtained through stand-
ardized questionnaires in connection with a physical ex-
amination, which included body weight, and non-fasting
blood samples. The serum was analyzed for cholesterol,
triglycerides, and the remaining volume frozen. After the
17 years of follow up stored serum was retrieved from
240 (89.5%) cases and 477 (89.0%) of the matched con-
trols.
Information on vital statistics, date of death until July 31
1997, breast cancer characteristics, and adjuvant treat-
ment, were achieved through linkage to the Civil Regis-
tration System, the Causes of Death Registry, and the
nation-wide clinical breast cancer trial conducted by the
Danish Breast Cancer Co-operative Group. The latter
was also able to provide information on where each
woman diagnosed with breast cancer was treated. This
made it possible to contact the pathology departments
where the tumor tissue had been reviewed. Paraffin em-
bedded tumor tissue was requested for estrogen receptor
status determination immunohistochemically by micro-
wave antigen retrieval, a mouse monoclonal anti-estro-
gen receptor antibody ER1D5, and the streptavidin-
biotin detection system [25]. The threshold for designa-
tion of estrogen receptor positivity was staining of >=
10% of the cell nuclei in the specimen.
Breast cancer characteristics included tumor size, degree
of spread, and stage of disease. Patients who were de-
fined as having received adjuvant therapy with
tamoxifen include those treated solely with tamoxifen,
and those who had a combination therapy including
tamoxifen.
The stored serum was analyzed for potential estrogenic
organochlorine compounds and their metabolites by the
U.S. Center of Disease Control and Prevention in Atlan-
ta: Hexachlorobenzene (HCB), dieldrin, polychlorinated
biphenyls (Σ PCB calculated as the sum of following con-
geners: IUPAC numbers 28, 52, 56, 66, 74, 99, 101, 105,
110, 118, 138, 146, 153, 156, 170, 172, 177, 178, 180, 183,
187, 189, 193, 194, 195, 201, 203, and 206), and p,p'-
DDE. The analytical technique involves a two-stage sol-BMC Cancer (2001) 1:8 http://www.biomedcentral.com/1471-2407/1/8
id-phase extraction and clean-up followed by dual-col-
umn gas-chromatographic separation and electron
capture detection [26]. To test for quality, bovine serum
was used to which three concentrations of 9 commercial
analytes were added. With every batch of 10 samples one
quality control and one reagent-blank sample was ana-
lyzed. All quality control results were compared with lim-
its established in the laboratory. If a quality sample was
not within control limits the samples in this batch were
discarded. Only completely resolved chromatographic
peaks area ratios were compared with a linear calibration
curve generated by analysis of standards of 6 different
concentrations in triplet. Recoveries were calculated by
subtracting the background level in the blank serum
from the level in the spiked serum and dividing by the
original spike concentration. The detection limit for all
analytes was based on two SD of the result from the low-
est control samples over the course of the analysis. The
detection limits on the evaluated compounds are: HCB
0.05 ng/mL, dieldrin 0.15 ng/mL, p,p'-DDE 0.41 ng/mL,
and varied for the PCB congeners from 0.13 ng/mL to
0.30ng/mL. For lipid adjustment the total serum lipid
concentration (mg/dl) was calculated as:
2.27  ×  cholesterol (mg/dl) + triglycerides (mg/dl) +
0.623 [27].
A total of 161 cases (67.1%) and their matched controls
(318 breast cancer free women) were eligible for analysis
of breast cancer risk according to ER. The case group
(161) served as a cohort in the survival analysis.
Organochlorine concentrations were categorized in four
levels of exposure using quartiles as cut-points. Associa-
tions between organochlorine exposure and breast can-
cer risk were examined by conditional logistic
regression. ERP and ERN tumors were analyzed sepa-
rately. The Cox proportional hazard method was used to
investigate tumor characteristics, and the influence of
organochlorine exposure on over all breast cancer sur-
vival [28]. The proportional hazard assumption was
checked by log (-log) plots from stratified analyses. All
variables included in the analyses complied with the as-
sumption. Odds ratios (OR), relative risks (RR), and 95%
confidence intervals (CI) were computed using SAS sta-
tistical software [29]. Body weight (kg, in quartiles), par-
ity (0, 1, ≥  2 children), menopausal status (pre- and
postmenopausal), hormone replacement therapy (never,
ever), smoking (never, ever), alcohol consumption (nev-
er or hardly ever, sometimes each month, sometimes
each week, every day), household income (<4000DKK,
4000-10000DKK, >10000DKK per month before tax),
and school education (<7, 7-10, >10 years) were included
in the risk analysis. Tumor size (actual size in mm, or
<50 mm, > 50 mm) degree of spread (axillary lymph
nodes with metastatic involvement: 0, > 1 nodes), and
stage of disease (early stage: tumor size <50 mm and de-
gree of spread 0 nodes; advanced stage: all other cases)
were included in the survival analyses as potential con-
founders. Backward step-wise procedures were used to
evaluate the modifying effect of the potential confound-
ers and other organochlorines. Only covariates that
reached statistical significance, were allowed to remain
in the model. Due to the observations with non-detecta-
ble organochlorine concentrations, a test for trend in risk
and prognosis was done using quartiles of organochlo-
rine concentrations. All performed tests of statistical sig-
nificance were two sided with a level of significance on
5%.
The study has been performed in accordance with the
Helsinki Declaration and approved by the Scientific Eth-
ical Committee serving Copenhagen and Frederiksberg
Municipality (KF) 01-157/94. Computerized linkage be-
tween Danish registries was performed according to
Danish legislation.
Results
The immunohistochemical estrogen receptor analysis
showed that 72.0% (116 cases) had developed an ERP
breast cancer and 28.0% (45 cases) an ERN cancers. Ta-
ble 1 shows the measured lipid adjusted serum organo-
chlorine concentration among these breast cancer cases.
High body weight, nulliparity, and use of hormone re-
placement therapy were identified as overall breast can-
cer risk factors (data not shown) and were therefore
included as covariates in the analyses of organochlorine
compounds. The excess risk of breast cancer associated
with high body weight and hormone replacement thera-
py after menopause derives from women who developed
and ERN breast cancer, but was not statistical significant
(table 2).
Table 1: Lipid adjusted serum concentrations of organochlorines 
among breast cancer cases with available estrogen receptor 
status.
Organochlorine Min – Max concentration 
(ppb)a
Median concentration 
(ppb)
HCB LODb – 1,901.50 269.75
Dieldrin LOD – 345.69 28.30
Σ PCB 156.84 – 2,621.21 1,076.04
p,p'-DDE 162.01 – 5,072.56 1,129.75
a Parts per billion; b Detection limitBMC Cancer (2001) 1:8 http://www.biomedcentral.com/1471-2407/1/8
The median duration of follow up with regard to death of
all causes was 7.2 years; a total of 125 breast cancer pa-
tients died.
The overall breast cancer survival was related to tumor
size, degree of spread, and stage of disease (data not
shown). These prognostic indicators were significantly
associated with breast cancer tumors that were ERN (ta-
ble 3).
Women with the highest serum concentration of dieldrin
had a more than seven-fold increased risk of developing
an ERN breast cancer compared to women with the low-
est concentration, and the risk increased in a stepwise
fashion with increasing dieldrin exposure level. No asso-
ciation could be observed for the ERP tumors (table 4).
The frequency of large tumors (size >50mm) at the high-
est dieldrin quartile exposure group was 27.3% (average
size, 37 mm) and 8.7% (average size, 27 mm) for ERN
and ERP tumors, respectively. The corresponding fig-
ures for spread of disease was 61.5% and 45.8%.
For the remainder of the organochlorine compounds,
ORs for the highest exposure level tended to be higher for
women who developed an ERP breast cancer than those
who had an ERN tumor, though none of the relation-
ships reached statistical significance (table 4). In gener-
al, the risk of dying among women with the highest
organochlorine exposure level was higher among women
with ERP than ERN breast cancers, but the only statisti-
cal significant relationship was observed for Σ PCB (table
5). A statistically significant inverse trend was seen for
exposure to HCB and Σ PCB in women with ERN tumors.
Exposure to dieldrin was associated with a significant in-
creased risk of dying for women with ERP tumors in the
second and third quartile compared to the first quartile.
An approximately 2-fold not significant increased risk of
dying among women in the highest dieldrin exposure
level compared to the lowest was observed for both ERP
and ERN tumors (table 5). Similar results were obtained
in analyses on a subgroup of 80 cases, where it was pos-
sible to adjust for tamoxifen therapy (data not shown).
Table 2: Breast cancer risk factors by estrogen receptor status.
Estrogen receptor positive Estrogen receptor negative
Factor Adjusted OR (95% 
CI)a
p trendb Adjusted OR (95% 
CI)
p trendb
Weight (kg) by quartile
<58 1.0 ref.c 1.0
58-64 0.7 (0.5-1.5) 1.3 (0.5-3.6)
65-71 1.1 (0.7-1.8) 1.9 (0.7-4.9)
>71 1.2 (0.7-1.9) >0.20 2.1 (0.8-5.9) 0.10
Number of full term pregnancies
01 . 0 1 . 0
1 1.0 (0.6-1.6) 1.7 (0.6-5.1)
>1 0.6 (0.4-0.9) 0.01 1.2 (0.5-3.1) >0.20
Hormone replacement-therapy
Never 1.0 1.0
Ever 1.1 (0.7-1.7) 1.8 (0.8-4.1)
a Odds ratio, 95% confidence interval, age-adjusted; b two sided p-value for linear trend in OR's, c reference category.
Table 3: Over all breast cancer survival in relation to clinical char-
acteristics and stage of disease by estrogen receptor status.
Estrogen receptor posi-
tive
Estrogen receptor neg-
ative
Characteristic Adjusted RR (95% CI)a Adjusted RR (95% CI)
Tumor size (mm)
<50 1.0 ref.b 1.0
≥  50 0.7 (0.2-3.0) 5.4 (1.8-15.9)
Metastatic lymph nodes
0 1.0 1.0
≥  1 1.6 (0.9-2.7) 4.6 (1.7-12.3)
Stage of disease
Early 1.0 1.0
Advanced 1.5 (0.9-2.6) 6.0 (2.1-16.9)
a Relative risk of dying, 95% confidence interval, adjusted for age at 
diagnosis; b reference category.BMC Cancer (2001) 1:8 http://www.biomedcentral.com/1471-2407/1/8
Including other organochlorines than the particular one
in question in the multivariate analysis did not have any
modifying effect on the observed estimates on breast
cancer risk and survival.
The cases on whom a tumor tissue specimen could not be
obtained were older at the time of entrance into the
CCHS (>60 years of age, 42.3% vs. 19.1%), older at the
time of diagnosis (>71 years of age at diagnosis, 32.1% vs.
19.1%), and more often nulliparous (nulliparity, 33.3%
vs. 24.1%) compared to those with an available speci-
men.
Discussion
It has been postulated that ERP and ERN breast cancers
represent different entities of the disease [7]. If this hy-
pothesis is correct the risk factor profiles may differ be-
tween the two types of breast cancer, especially for
hormone related factors as parity, hormone replacement
therapy and body weight. The present study's results on
these breast cancer risk factors according to ER are in ac-
cordance with previous epidemiological studies, which
do not provide consistent evidence to conclude that de-
velopment of ERP breast cancer is associated with expo-
sure to estrogen related factors [30–36].
Only few prior studies have evaluated the role of poten-
tial estrogenic organochlorines relationship to breast
cancer risk while accounting for estrogen receptor status
of the primary tumors. An excess risk of developing ERP
breast cancers associated with exposure to certain PCB
congeners, and DDE have been demonstrated [16,19].
The present study could not confirm this. In fact, the pre-
viously reported excess risk observed with exposure to
dieldrin derived from women who developed an ERN tu-
mor [13]. However, it is still uncertain what happens in
the preclinical phases of breast cancer development [37].
Low levels of available estrogen may stimulate estrogen
receptor expression [38]. It is also possible that down-
regulation of the estrogen receptor gene to immunohis-
to-chemically undetectable levels may occur in some tu-
mors due to high circulating levels of estrogens [38]. A
breast cancer initiated as an ERP cancer could therefor
change receptor status during the process of carcinogen-
esis prior to diagnosis. Thus ER status may merely repre-
sent different stages in disease progress.
Table 4: Risk of breast cancer in relation to serum concentrations of organochlorines in quartiles by estrogen receptor status.
Organochlorines Estrogen receptor positive Estrogen receptor negative
in quartiles (ng/mL) Cases/controls Adjusted RR (95% CI)a p trendb Cases/controls Adjusted OR (95% CI) p trend
HCB
I <206.50 36/56 1.0 ref.c 19/23 1.0
II 206.50-269.75 20/55 1.1 (0.6-1.8) 8/23 0.5 (0.2-1.4)
III 269.75-335.75 22/56 1.0 (0.6-1.7) 11/23 0.8 (0.3-2.2)
IV >335.75 36/55 1.2 (0.7-2.1) >0.20 6/23 0.4 (0.1-1.4) >0.20
Dieldrin
I <12.01 27/57 1.0 6/23 1.0
II 12.01-28.30 28/56 1.3 (0.7-2,2) 5/23 1.2 (0.3-5.4)
III 28.30-57.11 33/57 1.5 (0.8-2.7) 13/23 4.9 (0.9-28.3)
IV >57.11 28/56 1.4 (0.8-2.5) >0.20 20/23 7.6 (1.3-46.1) 0.01
Σ PCB
I <811.11 36/57 1.0 14/23 1.0
II 811.11-1076.04 24/56 1.1 (0.6-1.7) 11/23 1.0 (0.4-2.7)
III 1076.04-1405.73 20/57 0.7 (0.4-1.2) 11/23 1.3 (0.4-3.9)
IV >1405.73 36/56 1.3 (0.8-2.2) >0.20 8/23 0.8 (0.3-2.6) >0.20
p,p'-DDE
I <741.04 33/57 1.0 14/23 1.0
II 741.04-1129.75 29/56 0.7 (0.4-1.2) 11/23 0.9 (0.3-2.5)
III 1129.75-1688.85 25/57 0.8 (0.5-1.3) 10/23 0.7 (0.2-2.0)
IV >1688.85 29/56 0.9 (0.6-1.5) >0.20 9/23 0.6 (0.2-1.7) >0.20
a Odds ratio, 95% confidence interval, adjusted for age, weight, parity, and hormone replacement therapy; b two sided p-value for linear trend in 
OR's; c reference category. Cases with missing information on confounders were excluded.BMC Cancer (2001) 1:8 http://www.biomedcentral.com/1471-2407/1/8
Large tumors are more frequently heterogeneous with
respect to estrogen receptor expression than small tu-
mors [39–42]. Consequently, a greater proportion of the
large tumors will not exhibit estrogen reactivity at the
time of diagnosis, although some part of it will be ERP.
The tissue specimen obtained at the time of diagnosis
may therefor not necessary reflect the original initiated
breast cancer. These considerations may explain the
present study's finding on dieldrin, as 27.3% of the ERN
tumors among women in the highest exposure level had
a diameter above 50 mm, while the corresponding figure
for the ERP tumors was only 8.7%. Finally, it is possible
that dieldrin is associated with a yet unidentified factor
that modulates breast cancer risk.
Whether exposure to estrogen related risk factors or or-
ganochlorines with estrogenic potential results in devel-
opment of an ERP breast cancer cannot be determined
from current evidence, but deserves more attention in
future larger studies.
In the only study evaluating the influence of organochlo-
rines on overall survival of breast cancer, an adverse ef-
fect of dieldrin exposure was reported [24]. When the ER
of the tumor was taken into account in the analysis of
dieldrin, the relative risk of dying in the highest exposure
level was elevated in both patients with ERP and ERN tu-
mors, though not significantly. An adverse effect of diel-
drin on survival of women with ERP tumors could be
anticipated, as this compound is able to stimulate the
growth of human estrogen-sensitive cells [2]. Another
non-hormonal mechanism must lie behind the poorer
prognosis of women with ERN tumors. Possibly, expo-
sure to dieldrin may lead to development of a tumor with
an increased inherent aggressiveness beyond what this
study could take into account i.e. tumor size, degree of
spread, and stage of disease. The significantly poorer
prognosis observed for Σ PCB in women with ERP tumors
is in accordance with the hormonal potential of some
PCB congeners [1].
The breast cancer's responsiveness to estrogen is exploit-
ed in endocrine surgery by removing the ovaries, and
medically using drugs inhibiting the effects of estrogen
on tumor cell growth. Worldwide results indicate that a
20% reduction in the five-year mortality is achieved by
adjuvant therapy with tamoxifen in women over 50 years
of age [6]. The use of tamoxifen has become more fre-
quent and is not only reserved for postmenopausal pa-
tients or patients with ERP tumors, because a proportion
Table 5: Overall breast cancer survival in relation to serum concentrations of organochlorines by estrogen receptor status.
Organochlorines Estrogen receptor positive Estrogen receptor negative
in quartiles (ng/mL) Cases/control Adjusted RR (95% CI)a p trendb Cases/controls Adjusted RR (95% CI) p trend
HCB
I <206.50 13/15 1.0 ref.c 7/4 1.0
II 206.50-269.75 15/14 0.7 (0.3-1.6) 8/3 0.9 (0.3-3.1)
III 269.75-335.75 17/12 1.1 (0.5-2.4) 3/8 0.2 (0.0-1.2)
IV >335.75 13/15 1.1 (0.5-2.5) >0.20 4/7 0.2 (0.1-1.7) 0.03
Dieldrin
I <12.01 8/21 1.0 4/7 1.0
II 12.01-28.30 17/12 3.4 (1.3-8.7) 3/8 0.4 (0.1-3.1)
III 28.30-57.11 17/12 2.6 (1.0-6.3) 7/4 1.9 (0.5-7.8)
IV >57.11 17/12 2.2 (0.9-5.4) >0.20 8/3 1.8 (0.3-5.5) 0.06
Σ PCB
I <811.11 14/15 1.0 6/5 1.0
II 811.11-1076.04 15/14 1.5 (0.6-3.4) 7/4 0.4 (0.1-1.6)
III 1076.04-1405.73 13/16 1.0 (0.4-2.3) 5/6 0.5 (0.1-2.2)
IV >1405.73 17/12 2.5 (1.1-5.7) >0.20 4/7 0.1 (0.0-5.6) 0.02
p,p'-DDE
I <741.04 15/14 1.0 6/5 1.0
II 741.04-1129.75 13/16 0.7 (0.3-1.6) 4/7 0.3 (0.0-2.0)
III 1129.75-1688.85 17/12 1.0 (0.5-2.2) 5/6 0.7 (0.1-3.7)
IV >1688.85 14/15 1.0 (0.5-2.1) >0.20 7/4 0.3 (0.1-2.1) >0.20
a Relative risk of dying, 95% confidence interval, adjusted for age at diagnosis, metastatic lymph nodes, and tumor size; b two sided p-value for linear 
trend in RR's; c Reference category. Cases with missing information on confounders were excluded.BMC Cancer (2001) 1:8 http://www.biomedcentral.com/1471-2407/1/8
of up to 10% of ERN tumors is found to respond to the
therapy as well [43,44]. In this study tamoxifen was pref-
erably administered to postmenopausal patients, but
26.3% of the patients who received this treatment had an
ERN tumor. Tamoxifen competes with endogenous es-
trogen in binding to the receptor, and may therefore also
block a possible effect of an estrogenic compound. How-
ever, adjustment for tamoxifen therapy in survival anal-
yses on a sub-sample of the cohort (80 cases) did not
substantially alter the observed results. The present
study has several strengths. The participants were select-
ed independently of risk of breast cancer and were fol-
lowed for 17 years with regard to development of the
disease. This time span allows the breast cancer to devel-
op and takes into account the presumed long latency of
this cancer. Furthermore, it is possible to give a long-
term estimate for overall survival, as the median follow
up with regard to death was 7.2 years. The substantial
amount of information collected on the participants in
the CCHS and the linkage to several relevant registries
assured the ability to adjust for potential confounding,
when evaluating both breast cancer risk and prognosis.
The observed differences between cases eligible for and
not eligible for assessing ER are unlikely to have affected
the findings on breast cancer risk. Parity would be ex-
pected to be associated with lower organochlorine con-
centrations, as lactation is a main route by which these
substances are excreted. Younger age would mean short-
er duration of exposure and less accumulation. Thus, the
study subjects included in the present study could have
lower serum organochlorine concentrations and slightly
lower risk of breast cancer than the CCHS cohort in gen-
eral. Exclusion of cases diagnosed within 5 years of se-
rum sampling did not affect the present results on risk
and survival, and neither did mutual adjustment for or-
ganochlorine compounds.
The Danish unique 10-digit ID-number issued to all per-
sons living in and entering the country (by birth or immi-
gration) insure the completeness of the undertaken
linkages. Since 1942, the Danish Cancer Registry has reg-
istered all cases of cancer occurring in the entire Danish
population; the registry is regarded virtually complete
[45]. DBCG has since 1976 been notified about new
breast cancer cases by all Danish hospital departments
[46].
The present study was not designed as a classical survival
study and blood samples for assessment of organochlo-
rine exposure was taken on average 8.7 years before the
patients were diagnosed with breast cancer. Given the
changes in organochlorine concentrations over time, the
study only indirectly addressed the question whether es-
trogen or estrogenic compounds determined in 1976-78
may interfere with the prognosis of ERP tumors. On the
other hand, breast cancer is estimated to take several (8-
10) years to reach a clinical detectable size, which mean
that assessment of organochlorine exposure at the time
of diagnosis will not reflect the level at tumor initiation.
Even though this study included more breast cancer cas-
es than most of the previous studies dealing with the or-
ganochlorine issue, it still has limited statistical power,
especially in the analyses of ERN tumors.
Conclusion
The present study does not support the hypothesis that
estrogen related risk factors or potential estrogenic orga-
nochlorines increase the risk of developing ERP tumors.
In fact, it shows that exposure to dieldrin increases the
risk of developing ERN tumors, which are larger and
more often spread at the time of diagnosis. However, this
finding should be interpreted with caution due to the
limited number of ERN cases, so whether exposure to es-
trogenic organochlorine compounds affect the risk and
prognosis of a hormone-responsive breast cancer needs
to be clarified.
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